Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic
- Publication date
- 1 August 2020
- Publisher
- 'Royal College of Obstetricians & Gynaecologists (RCOG)'